Yes — you can absolutely get a second opinion on an Alzheimer’s diagnosis, and in many cases you should. There is no medical rule or insurance barrier preventing it: Medicare, for example, covers second opinions under Part B for any service it normally covers, and will even cover a third opinion if the first two disagree. Doctors themselves expect it. The National Institute on Aging notes that primary-care physicians commonly refer patients to specialists — neurologists, geriatricians, geriatric psychiatrists, and neuropsychologists — precisely because a detailed, confirmatory diagnosis often requires expertise a general practice can’t provide. The case for a second opinion is not just about peace of mind.
Autopsy studies from the NIA’s Alzheimer’s Disease Centers between 2005 and 2010 found that clinical Alzheimer’s diagnoses were wrong in roughly one in four to five cases: sensitivity ranged from 70.9 to 87.3 percent, and specificity — the ability to correctly rule out Alzheimer’s — was as low as 44.3 percent against neuropathology. Consider a 72-year-old told she has Alzheimer’s after a brief office visit and a short cognitive screen. A specialist re-evaluation might instead uncover normal pressure hydrocephalus — a treatable condition marked by gait problems, urinary urgency, and cognitive decline — or a severe vitamin B12 deficiency. Either finding would change everything about her prognosis and treatment. A second opinion in this context means more than a second doctor’s impression. It can include re-evaluation at a memory clinic, confirmatory biomarker testing with a PET scan, spinal fluid analysis, or a newly cleared blood test, and a systematic effort to rule out reversible conditions that mimic dementia.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Can You Really Get a Second Opinion on an Alzheimer’s Diagnosis — and Who Gives It?
- How Often Are Alzheimer’s Diagnoses Wrong?
- Conditions That Mimic Alzheimer’s — Some of Them Reversible
- Biomarker Testing: The Blood Test, PET Scans, and Spinal Fluid
- When a Second Opinion Changes the Plan — and When It Complicates It
- What a Second Opinion Costs and How Insurance Handles It
- How to Actually Request One Without Offending Your Doctor
- Frequently Asked Questions
Can You Really Get a Second Opinion on an Alzheimer’s Diagnosis — and Who Gives It?
Not only can you get one, there is an established institutional path for doing so. According to the NIA, the typical route runs from a primary-care doctor to one of several kinds of specialists: a neurologist (nervous system diseases), a geriatrician (aging and complex older-adult health), a geriatric psychiatrist (mood and cognition in older adults), or a neuropsychologist (detailed cognitive testing). Any of these can serve as the second set of eyes on a diagnosis made in primary care — or on one made by another specialist.
For complex or ambiguous cases, the strongest option is a memory disorders clinic or one of the NIA-funded Alzheimer’s Disease Research Centers, which accept referrals. These centers use a team model — neurology, geriatrics, psychiatry, neuropsychology, and imaging working together — which matters because dementia diagnosis is not one test but a synthesis of history, cognitive testing, imaging, and lab work. The comparison is instructive: a primary-care visit might involve a ten-minute cognitive screen like the MoCA, while a memory-clinic workup can involve hours of neuropsychological testing, structural brain imaging, and blood work reviewed by multiple specialists. Those are very different levels of diagnostic certainty.
How Often Are Alzheimer’s Diagnoses Wrong?
More often than most families assume. The definitive check on a clinical Alzheimer’s diagnosis is autopsy, and the numbers are sobering. In the 2012 study of NIA Alzheimer’s Disease Centers covering 2005–2010 — published in the Journal of Neuropathology & Experimental Neurology — clinical diagnosis missed real Alzheimer’s pathology in a meaningful share of cases and, more strikingly, labeled people as having Alzheimer’s when autopsy showed something else. Specificity as low as 44.3 percent means that in some settings, a large fraction of “Alzheimer’s” patients actually had a different disease process. What did those patients actually have? The autopsy cohort included tangle-only dementia and argyrophilic grain disease, frontotemporal lobar degeneration, cerebrovascular disease, Lewy body disease, and hippocampal sclerosis.
These distinctions are not academic. Lewy body disease, for instance, carries serious sensitivity to certain antipsychotic medications; frontotemporal degeneration affects younger patients and behaves very differently; vascular disease calls for aggressive cardiovascular management. One important limitation: these error rates come from specialized research centers with experienced clinicians. And a second opinion is not a guarantee of certainty — even biomarker-confirmed diagnoses describe brain pathology, not a perfect prediction of how symptoms will unfold. A second opinion reduces uncertainty; it does not eliminate it.
Conditions That Mimic Alzheimer’s — Some of Them Reversible
Perhaps the strongest argument for a second opinion is that several conditions produce Alzheimer’s-like symptoms and are partly or fully reversible when correctly identified. AARP’s review of medical problems that mimic dementia lists vitamin B12 deficiency, thyroid disorders, normal pressure hydrocephalus, medication side effects, infections, and depression. Every one of these has a treatment path that Alzheimer’s does not. Normal pressure hydrocephalus is the classic example.
It presents with a triad — gait disturbance, urinary problems, and cognitive decline — that can be mistaken for Alzheimer’s, yet it is treatable with a surgically placed shunt that drains excess cerebrospinal fluid. Similarly, an older adult taking multiple medications with anticholinergic effects (common in sleep aids, bladder drugs, and some antidepressants) can develop confusion and memory problems that resolve when the medications are adjusted. Depression in older adults, sometimes called pseudodementia when it impairs cognition, responds to treatment in a way no neurodegenerative disease does. A thorough second opinion should include blood work for B12 and thyroid function, a careful medication review, and screening for mood disorders before the Alzheimer’s label is accepted as final.
Biomarker Testing: The Blood Test, PET Scans, and Spinal Fluid
A modern second opinion increasingly means biomarker confirmation — objective evidence of the amyloid plaques that define Alzheimer’s pathology. In May 2025, the FDA cleared the first blood test to help diagnose Alzheimer’s: the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio from Fujirebio. It measures plasma pTau217 and β-amyloid 1-42 to indicate whether amyloid plaques are likely present. Its reported agreement with the older gold standards is strong: about 91.7 percent of positive results corresponded to confirmed amyloid plaques on PET or spinal fluid testing, and about 97.3 percent of negative results showed no amyloid, per Mayo Clinic’s summary. The tradeoffs among the three biomarker routes are practical ones.
The blood test is the least invasive and cheapest, but it is an aid to diagnosis, not a standalone answer — it is intended for adults 50 and older who already have cognitive symptoms, and it is explicitly not recommended for screening healthy people. Amyloid PET imaging is more definitive but more expensive and involves radiation. Cerebrospinal fluid analysis via lumbar puncture is highly accurate but invasive. Access to PET has improved considerably: CMS removed its prior once-per-lifetime, clinical-trial-only restriction, so Medicare now covers amyloid PET scans for confirming an Alzheimer’s diagnosis. For families weighing a contested or uncertain diagnosis, the blood test is often a sensible first confirmatory step, with PET or CSF reserved for ambiguous results.
When a Second Opinion Changes the Plan — and When It Complicates It
Confirmatory testing is not a formality; it frequently changes what doctors do. In the IDEAS study of Medicare beneficiaries with mild cognitive impairment or atypical dementia, amyloid PET results changed clinical management in more than 60 percent of cases — altering diagnoses, medications, or care plans. That is a remarkable figure: for a majority of patients in diagnostically uncertain situations, one confirmatory scan redirected their care. But there are complications worth anticipating.
A second opinion can produce a conflicting answer rather than a cleaner one — which is exactly why Medicare covers a third opinion when the first two disagree. Biomarker results can also create their own ambiguity: amyloid plaques are common in cognitively normal older adults, so a positive amyloid test in someone with mild symptoms does not by itself prove that Alzheimer’s is causing those symptoms, and mixed pathologies (Alzheimer’s plus vascular disease plus Lewy bodies) are common in advanced age. A warning for families: be cautious about direct-to-consumer testing outside a physician’s care. The FDA-cleared blood test is meant to be ordered and interpreted by clinicians for symptomatic patients — a result without clinical context can mislead more than it informs.
What a Second Opinion Costs and How Insurance Handles It
For Medicare beneficiaries, the financial barrier is lower than many expect. Medicare Part B covers second opinions for any service Medicare normally covers, subject to the usual Part B cost-sharing, and covers a third opinion if the first two conflict.
With CMS’s expanded coverage of amyloid PET, the imaging component of a confirmatory workup is also within reach for beneficiaries whose doctors order it. A practical example: a patient diagnosed by their internist can ask for a referral to a neurologist or an NIA-funded Alzheimer’s Disease Research Center, have the consultation billed to Part B like any specialist visit, and — if the specialist recommends it — proceed to biomarker testing under the same coverage framework rather than paying out of pocket.
How to Actually Request One Without Offending Your Doctor
The mechanics are simpler than the social discomfort. Ask your diagnosing physician directly for a referral — the NIA describes specialist referral as a routine part of the diagnostic process, not a challenge to the doctor’s competence, and most physicians welcome confirmation in a disease this consequential.
Request copies of all records first: cognitive test scores, imaging, and lab results, so the second clinician isn’t starting from zero. If your area has an NIA-funded Alzheimer’s Disease Research Center, ask specifically about referral there, since these centers accept outside referrals and bring a full multidisciplinary team — neurology, geriatrics, psychiatry, neuropsychology, and imaging — to a single case. Bring a family member who can describe symptom onset and progression; in memory disorders, the history from someone who lives with the patient is often the single most valuable piece of diagnostic evidence.
Frequently Asked Questions
Does Medicare pay for a second opinion on an Alzheimer’s diagnosis?
Yes. Medicare Part B covers second opinions for services Medicare normally covers, and covers a third opinion if the first two disagree.
What kind of doctor should give the second opinion?
A neurologist, geriatrician, geriatric psychiatrist, or neuropsychologist — or ideally a memory disorders clinic or NIA-funded Alzheimer’s Disease Research Center, which use a team-based approach.
Is there a blood test that can confirm Alzheimer’s?
The FDA cleared the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test in May 2025. It aids diagnosis in adults 50+ with cognitive symptoms but is not a standalone or screening test.
What conditions can be mistaken for Alzheimer’s?
Reversible mimics include vitamin B12 deficiency, thyroid disorders, normal pressure hydrocephalus, medication side effects, infections, and depression. Autopsy studies also found Lewy body disease, frontotemporal degeneration, and vascular disease misdiagnosed as Alzheimer’s.
How often is a clinical Alzheimer’s diagnosis wrong?
Autopsy data from NIA Alzheimer’s Disease Centers (2005–2010) suggest roughly one in four to five clinical diagnoses did not match the brain pathology found at autopsy.
